SFM
VRDN icon

Sphera Funds Management’s Viridian Therapeutics VRDN Stock Holding History

Sphera Funds Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-86,094
Closed -$1.96M – 133
2024
Q3 		$1.96M Buy
+86,094
New +$1.41M 0.31% 84
2021
Q1 		– Sell
-30,497
Closed -$502K – 201
2020
Q4 		$502K Buy
+30,497
New +$460K 0.04% 104

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Sphera Funds Management's VRDN Position: Q4 2024 in Review

Sphera Funds Management sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 86,094 shares — an estimated $1.96M sold.

Sphera Funds Management first reported a position in VRDN in Q4 2020 and held it in 2 quarters. The position peaked at $1.96M in Q3 2024. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

  • Sphera Funds Management reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sphera Funds Management sold 86,094 Viridian Therapeutics shares in Q4 2024, an estimated $1.96M.
  • Sphera Funds Management first reported a position in Viridian Therapeutics in Q4 2020 and held it in 2 quarters.
  • Sphera Funds Management's Viridian Therapeutics position peaked at $1.96M in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on Sphera Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.